Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
News and Events
by Jane Barlow
The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties which complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and ultimately, future developer innovation. The Financing and Reimbursement of Cures in the U.S. (FoCUS) project was launched in 2016 by MIT with the objective of elucidating the challenges and financial impact created by durable/potentially curative therapies and providing implementable models to manage the financial impact on the U.S. healthcare system.
January 9, 2020
PharmExec.comread full article >
Panel: Drug Pricing and Value Based Reimbursement
Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors -- about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.
October 13, 2019
October 15, 2019
Laguna Beach, CA
by University of Colorado
Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), to women under the age of 35. It represents a first-of-its-kind published analysis of results from a risk-sharing agreement between biotechnology company Illumina, Inc. and insurer Harvard Pilgrim Health Care, conducting the research in partnership with advisory firm Real Endpoints to evaluate the impacts of the agreement.
October 8, 2019
EurekAlertread full press release >
Recent Insightsview archive >
November 14, 2019
Consolidation on the payer side is changing the dynamics of success in health care. Principals at Real Endpoints LLC examineread full insight article >
June 11, 2019
Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.read full insight article >
National Business Director
Top 5 Pharma
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
President , GlaxoSmithKline U.S.